59 completed, 5 recruiting, 4 not yet recruiting, 4 terminated. 81 Phase 2, 6 Phase 1, 5 Phase 3.
Follow Crystal Arthropathies: new trials by email Literature Review of Crystal Arthropathies trials Research Report on Crystal Arthropathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment Colchicine Pill, Placebo - CPPD - Calcium Pyrophosphate Deposition Disease | Phase 2 | Recruiting | Brigham and Women's Hospital | 150 | 2026-08-12 | 2026-09-21 |
| A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment SSGJ-613 100 mg Q12W, SSGJ-613 200 mg Q12W, SSGJ-613 100 mg Q4W - Gout Arthritis | Phase 2 | Not yet recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 200 | 2026-08-02 | 2026-07-20 |
| A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants Dotinurad, Placebo - Gout | Phase 2 | Recruiting | Crystalys Therapeutics | 90 | 2026-05-08 | 2026-09-28 |
| Tocilizumab in Chronic Inflammatory CPPD Disease Tocilizumab, Placebo - Calcium Pyrophosphate Deposition Disease | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 80 | 2026-04-01 | 2026-01-14 |
| Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia BR2251, Febuxostat - Gout and Hyperuricemia | Phase 2 | Not yet recruiting | BioRay Pharmaceutical Co., Ltd. | 160 | 2026-04-01 | 2026-03-27 |
| A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE) PRX-115, Methotrexate (MTX), PRX-115 placebo - Gout | Phase 2 | Recruiting | Protalix | 150 | 2025-12-22 | 2026-09-29 |
| Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients AR882 75 mg, XOI Low Dose, XOI High Dose - Gout, Gouty Arthritis | Phase 2 | Active not recruiting | Arthrosi Therapeutics | 15 | 2025-12-03 | 2026-05-15 |
| Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare ABP-745 Dose A, ABP-745 Dose B, Colchicine - Acute Gouty Arthritis, Gout Flare | Phase 2 | Completed | Atom Therapeutics Co., Ltd | 479 | 2025-08-26 | 2026-10-28 |
| Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients Febuxostat Tablets, Metformin - Gout | Phase 2 | Completed | Mostafa Bahaa | 60 | 2025-05-30 | 2026-09-17 |
| Metformin in Safety and Efficacy in Gouty Patients placebo, Metformin - Gout | Phase 2 | Recruiting | Mostafa Bahaa | 70 | 2025-04-20 | 2026-09-30 |
| Baricitinib in CPPD - the BAPTIST Study Baricitinib 4 MG Oral Tablet, Methylprednisolone (Corticosteroid), Colchicine 1 MG Oral Tablet - Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis | Phase 2 | Not yet recruiting | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | 32 | 2025-01-01 | 2025-01-10 |
| A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects Febuxostat, IBI128 - Gout, Hyperuricemia | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 84 | 2024-07-10 | 2025-03-27 |
| PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function SAP-001 - Gout, Hyperuricemia | Phase 1 / Phase 2 | Active not recruiting | Shanton Pharma Pte. Ltd. | 32 | 2024-04-24 | 2024-12-11 |
| Extension Study of ABP-671 in Participants With Gout ABP-671, Allopurinol - Gout | Phase 2 / Phase 3 | Terminated | Atom Therapeutics Co., Ltd | 43 | 2024-04-22 | 2025-07-16 |
| Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia Febuxostat 20MG Tablets, Febuxostat 20MG Placebo, AR882 25MG - Primary Gout, Hyperuricemia | Phase 2 / Phase 3 | Unknown | Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd | 636 | 2024-04-22 | 2024-09-19 |
| A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment. Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg, Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, Colchicine 0.5 mg - Gout Arthritis | Phase 2 | Unknown | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 157 | 2024-03-30 | 2024-08-05 |
| Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia dotinurad, dotinurad + allopurinol, allopurinol - Gout, Hyperuricemia | Phase 1 / Phase 2 | Completed | Urica Therapeutics Inc. | 20 | 2023-10-04 | 2026-06-10 |
| Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout ABP-671, Allopurinol, Placebo - Gout | Phase 2 / Phase 3 | Completed | Atom Therapeutics Co., Ltd | 300 | 2023-08-11 | 2025-12-22 |
| A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202) Genakumab for injection, Colchicine - Gout, Gout Initiating Urate-loweringUrate-lowering Therapy | Phase 2 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 165 | 2023-07-20 | 2025-01-01 |
| Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout D-0120, Allopurinol - Gout | Phase 2 | Completed | InventisBio Co., Ltd | 80 | 2023-04-17 | 2026-07-09 |
Showing 20 of 81. Sign in to see all of them.
Gout (71) · Hyperuricemia (37) · Arthritis, Gouty (12) · Arthritis (4) · Renal Insufficiency, Chronic (4) · Chondrocalcinosis (3) · Joint Diseases (2) · Renal Insufficiency (2) · Arthralgia (1) · Inflammation (1) · Pain (1) · Rotator Cuff Tear Arthropathy (1)
Musculoskeletal Diseases (81) · Joint Diseases (79) · Arthritis (77) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (77) · Genetic Diseases, Inborn (77) · Metabolic Diseases (77) · Metabolism, Inborn Errors (77) · Nutritional and Metabolic Diseases (77) · Purine-Pyrimidine Metabolism, Inborn Errors (77) · Rheumatic Diseases (77) · Pathological Conditions, Signs and Symptoms (40) · Pathologic Processes (39) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6)
Febuxostat (18) · Colchicine (16) · Allopurinol (14) · verinurad (6) · arhalofenate (5) · canakinumab (4) · ulodesine (4) · Interleukin 1 Receptor Antagonist Protein (3) · Pegloticase (3) · Metformin (2) · Methotrexate (2) · Triamcinolone Acetonide (2) · URC102 (2) · diacerein (2) · dotinurad (2)
Gilead Sciences (5) · Takeda (5) · Ardea Biosciences, Inc. (4) · Arthrosi Therapeutics (4) · Atom Therapeutics Co., Ltd (4) · BioCryst Pharmaceuticals (4) · AstraZeneca (3) · JW Pharmaceutical (3) · Allena Pharmaceuticals (2) · Assistance Publique - Hôpitaux de Paris (2) · InventisBio Co., Ltd (2) · Mostafa Bahaa (2) · Novartis (2) · Novartis Pharmaceuticals (2) · Nuon Therapeutics, Inc. (2)
United States (51) · Taiwan (8) · United Kingdom (8) · China (7) · Australia (5) · Georgia (5) · Canada (4) · France (4) · Guatemala (4) · Poland (4) · Russia (4) · Spain (4) · Argentina (3) · Belgium (3) · Germany (3)
Alan Hollister, MD, PhD (2) · C Tosone, MS, RAC (2) · John S. Sundy, MD, PhD (2) · R Keenan, MD (2) · Alexandra Steinberg, MD, PhD (1) · Carmen Arencibia (1) · Celina Cabale-Scholl, DPT, RN (1) · Chang-Youh Tsai (1) · Chris Smith (1) · Christopher Wynne, MBChB, Grad Dip Pharm Med (1) · Georgios Filippou, Assistant Professor (1) · Gowrie Balasubramaniam, MB ChB (1)
PMID 16911575, PMID 32951150, PMID 15751090, PMID 18759308, PMID 19141576, PMID 20533546, PMID 20660758, PMID 21169856, PMID 21372003, PMID 21439048, PMID 21540198, PMID 21572152, PMID 22223180, PMID 24122883, PMID 24602182, PMID 26742777, PMID 26894653, PMID 26989892, PMID 27980008, PMID 28877949, PMID 28975718, PMID 29531784, PMID 29657831, PMID 29848361, PMID 29868853, PMID 33075806, PMID 33605029, PMID 34882311, PMID 35365187, PMID 40420308, PMID 41388232, PMID 42816092
2015 (1)